Healthcare provider profile · identity verified

Thanh Duc Bui, MD

Family Practice · ANAHEIM, CA · NPI 1730250622

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	639	319
Amlodipine Besylate	Amlodipine Besylate	435	189
Losartan Potassium	Losartan Potassium	310	142
Simvastatin	Simvastatin	276	108
Levothyroxine Sodium	Levothyroxine Sodium	248	105
Lisinopril	Lisinopril	220	114
Rosuvastatin Calcium	Rosuvastatin Calcium	219	104
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	195	83
Glipizide	Glipizide	193	87
Metformin Hcl Er	Metformin Hcl	188	80
Atenolol	Atenolol	183	93
Metformin Hcl	Metformin Hcl	166	80
Omeprazole	Omeprazole	156	89
Alendronate Sodium	Alendronate Sodium	150	63
Tamsulosin Hcl	Tamsulosin Hcl	147	70
Hydrochlorothiazide	Hydrochlorothiazide	126	65
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	124	29
Metoprolol Tartrate	Metoprolol Tartrate	117	55
Trazodone Hcl	Trazodone Hcl	99	45
Allopurinol	Allopurinol	94	40
Albuterol Sulfate Hfa	Albuterol Sulfate	93	66
Terazosin Hcl	Terazosin Hcl	91	34
Meloxicam	Meloxicam	87	57
Finasteride	Finasteride	85	38
Gabapentin	Gabapentin	85	40
Pantoprazole Sodium	Pantoprazole Sodium	78	44
Jardiance	Empagliflozin	72	34
Bisoprolol Fumarate	Bisoprolol Fumarate	61	21
Triamcinolone Acetonide	Triamcinolone Acetonide	61	36
Potassium Chloride	Potassium Chloride	60	29
Pradaxa	Dabigatran Etexilate Mesylate	57	30
Fluoxetine Hcl	Fluoxetine Hcl	50	21
Furosemide	Furosemide	48	29
Ibuprofen	Ibuprofen	45	21
Clopidogrel	Clopidogrel Bisulfate	36	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	35	18
Sertraline Hcl	Sertraline Hcl	35	19
Fenofibrate	Fenofibrate	34	13
Wixela Inhub	Fluticasone Propion/Salmeterol	34	18
Pravastatin Sodium	Pravastatin Sodium	30	15
Naproxen	Naproxen	28	12
Lovastatin	Lovastatin	26	14
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	26	12
Spironolactone	Spironolactone	26	12
Hydrocortisone	Hydrocortisone	25	18
Pioglitazone Hcl	Pioglitazone Hcl	25	13
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	23	suppressed
Carvedilol	Carvedilol	22	11
Colchicine	Colchicine	22	suppressed
Ezetimibe	Ezetimibe	22	12
Humulin N	Insulin Nph Human Isophane	22	suppressed
Metoprolol Succinate	Metoprolol Succinate	22	12
Acyclovir	Acyclovir	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	21	suppressed
Tramadol Hcl	Tramadol Hcl	21	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	20	18
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	12
Clonazepam	Clonazepam	19	suppressed
Nystatin	Nystatin	19	12
Prednisone	Prednisone	19	19
Temazepam	Temazepam	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	18	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	17	suppressed
Nifedipine Er	Nifedipine	17	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	16	16
Alprazolam	Alprazolam	16	suppressed
Famotidine	Famotidine	16	suppressed
Spiriva Respimat	Tiotropium Bromide	16	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	16	11
Warfarin Sodium	Warfarin Sodium	16	suppressed
Amoxicillin	Amoxicillin	15	14
Chlorthalidone	Chlorthalidone	14	suppressed
Eliquis	Apixaban	13	suppressed
Fluticasone Propionate	Fluticasone Propionate	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Topiramate	Topiramate	13	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	12	12
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Tacrolimus	Tacrolimus	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error